Recruiting for COVID clinical trial

SaNOtize has been evaluating nitric oxide (NO), a naturally occurring nanomolecule in the body, as a first-in-class nitrosylite drug with the potential to be used as a topical antimicrobial agent to treat a wide variety of diseases.

SaNOtize has an issued patent on a Nitric Oxide Releasing Solution (NORSTM).

The SaNOtize vision is to provide a first-line non-antibiotic antimicrobial for initial use against bacterium, viruses and fungi. In doing so, antibiotic therapies may be saved for more severe infections, used less frequently, and ultimately slow the development of antimicrobial resistance.

In addition to it’s ability to treat a broad spectrum of infectious pathogens, NORSTM delivery is practical and convenient. Having developed a proprietary liquid formulation to generate NO as an antimicrobial and immunomodulatory agent, high pressure cylinders of gNO are not required for delivery.

Patented NORSTM Technology

  • Stable Storage
  • Low manufacturing cost and scalable
  • Established safety profile
  • Can be delivered topically as liquid/gel
logged in